Showing 61 - 74 results of 74 for search '"platelet aggregation"', query time: 0.05s Refine Results
  1. 61

    Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects by Kaitlin Garofano, Vera Mariani, Kameron Rashid, Sumanun Suwunnakorn, Alfateh Sidahmed, Anelia Horvath, Sanjay B. Maggirwar, Travis J. O’Brien, Minoli A. Perera, Michael Whalen, Norman H. Lee

    Published 2025-12-01
    “…We have previously demonstrated that platelets physically couple to MDA-PCa-2b and RC77T/E prostate cancer (PCa) cells via specific ligand-receptor interactions, leading to platelet-stimulated cell invasiveness and apoptotic resistance, and reciprocal cell-induced platelet aggregation. In contrast, PLP interactions with PCa cells inhibited both cell invasion and apoptotic resistance while failing to promote PLP aggregation. …”
    Get full text
    Article
  2. 62

    The Application of Biologically Active Components Derived from Mineral, Synthetic, Phyto- and Organic Sources for Developing Local Hemostatic Agents: Historical Traditions and Cont... by S. Abramov, S. Sokolovskyi, A. Gozhenko, I. Sobko, G. Titov, V. Gladyshev, M. Khmil, Ugis Kletnieks

    Published 2025-01-01
    “…These components can act through various mechanisms, such as inducing platelet aggregation, activating the coagulation cascade, or promoting the formation of blood clots. …”
    Get full text
    Article
  3. 63

    The Platelet-Specific Gene Signature in the Immunoglobulin G4-Related Disease Transcriptome by Ali Kemal Oguz, Cagdas Sahap Oygur, Bala Gur Dedeoglu, Irem Dogan Turacli, Sibel Serin Kilicoglu, Ihsan Ergun

    Published 2025-01-01
    “…Among these, a molecular signature of 22 platelet-specific genes harbored genes important for leukocyte–platelet aggregate formation (i.e., <i>CLEC1B</i>, <i>GP1BA</i>, <i>ITGA2B</i>, <i>ITGB3</i>, <i>SELP</i>, and <i>TREML1</i>) and extracellular matrix synthesis (i.e., <i>CLU</i>, <i>PF4</i>, <i>PPBP</i>, <i>SPARC</i>, and <i>THBS1</i>). …”
    Get full text
    Article
  4. 64

    A nonactivating ITGB3 mutation in the β3 cytoplasmic region causes macrothrombocytopenia with an impaired αIIbβ3/RhoA pathway by Keiichi Nakata, Keigo Akuta, Takaya Endo, Midori Koike, Daisuke Motooka, Daisuke Okuzaki, Hisashi Kato, Yoshiaki Tomiyama, Naoki Hosen, Hirokazu Kashiwagi

    Published 2025-02-01
    “…Thus, the hetero KI mice reproduced the phenotype of the human participant, indicating that the β3(R760C) mutation is responsible for the macrothrombocytopenia. Platelet aggregation, agonist-induced JON/A binding, and P-selectin expression were impaired in KI mice. …”
    Get full text
    Article
  5. 65

    Gambaran Kadar Troponin T dan Creatinin Kinase Myocardial Band pada Infark Miokard Akut by Rendi Dwi Prasetyo, Masrul Syafri, Efrida .

    Published 2014-09-01
    “…<br />Kata kunci: infark miokard akut, troponin t, CKMB</p><p>Abstract<br />Acute Myocardial Infarction (AMI) is a muscle necrosis of the heart caused by rupture atherosclerotic plaque from one of coronary artery that cause platelet aggregation, thrombus formation, and coronary spasm. …”
    Get full text
    Article
  6. 66

    Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis by Minjing Zou, Amal Qattan, Monther Al-Alwan, Hazem Ghebeh, Naif Binjumah, Latifa Al-Haj, Khalid S. A. Khabar, Abdulmohsen Altaweel, Falah Almohanna, Abdullah M. Assiri, Abdelilah Aboussekhra, Ali S. Alzahrani, Ali S. Alzahrani, Yufei Shi

    Published 2025-02-01
    “…Furthermore, Met cells showed robust overexpression of Tbxas1, a thromboxane A synthase 1 gene that catalyzes the conversion of prostaglandin H2 to thromboxane A2 (TXA2), a potent inducer of platelet aggregation. Application of aspirin, a TXA2 inhibitor, significantly reduced lung metastases. …”
    Get full text
    Article
  7. 67

    Effect of Rifaximin and a Multi-Strain Probiotic on the Intestinal Microbiome and Cardiovascular Risk Indicators in Patients with Coronary Heart Disease by E. A. Kashukh, E. A. Poluektova, A. V. Kudryavtseva, G. S. Krasnov, V. I. Kazey, P. D. Sobolev, P. V. Gremyakova, V. T. Ivashkin

    Published 2019-09-01
    “…An additional administration of the probiotic (Bifidobacterium bifidum no less than 1x109 CFU; Bifidobacterium longum no less than 1x109 CFU; Bifidobacterium infantis no less than 1x109 CFU; Lactobacillus rhamnosus no less than 1x109 CFU) is found to have no effect on the lipid profile and the platelet aggregation rate. Rifaximin therapy reduced the amount of total cholesterol, low density lipoproteins (LDL), very low density (VLDL) lipoproteins and triglycerides (p &lt;0.05), although not affecting the level of high density lipoproteins (HDL). …”
    Get full text
    Article
  8. 68

    Thrombus composition and its implication in ischemic stroke assessment and revascularization treatments by Juan Marta-Enguita, Florencio J.D. Machado, Josune Orbe, Roberto Muñoz

    Published 2025-01-01
    “…However, other factors such as clot formation time, associated inflammatory status, or activation of additional immune and coagulation pathways (neutrophil extracellular trap [NET] delivery, platelet aggregation, endothelial activation, and von Willebrand Factor release) have been described as determinants in thrombus characteristics. …”
    Get full text
    Article
  9. 69

    Composición del trombo e implicaciones en la caracterización y el tratamiento en el ictus isquémico by J. Marta-Enguita, F.J.D. Machado, J. Orbe, R. Muñoz

    Published 2025-01-01
    “…Other factors as clot formation time, associated inflammatory status or activation of additional immune and coagulation pathways (Neutrophil extracellular traps [NETs] delivery, platelet aggregation, endothelial activation and Von Willebrand Factor release) have been described as determinants in thrombus characteristics. …”
    Get full text
    Article
  10. 70

    Clinical observation of Shenfu injection in treating patients with internal watershed cerebral infarction (参附注射液治疗内分水岭脑梗死临床观察) by YANG Junhang (杨俊行), LI Jie (李杰), HU Zhe (胡哲), FU Jingna (付景娜), FENG Huimin (冯慧敏)

    Published 2021-10-01
    “…All cases received a comprehensive treatment including anti-platelet aggregation, lowering blood lipid, regulating blood pressure, replenishing blood volume, improving microcirculation and protecting brain cells. …”
    Get full text
    Article
  11. 71

    Nicotine’s impact on platelet function: insights into hemostasis mechanisms by Xiayu Wu, Xiayu Wu, Yongjun Liu, Changhao Zou, Changhao Zou, Fuqin He, Fuqin He, Fang Guo, Fang Guo, Sijia Liu, Sijia Liu, Yi Fan, Yi Fan, Xuedong Zhu, Xuedong Zhu, Qianyi Zhou, Qianyi Zhou, Dan Shu, Dan Shu

    Published 2025-01-01
    “…While nicotine is known to enhance platelet aggregation, its effects on other platelet functions and underlying mechanisms remain unclear.Methods and ResultsThis study aimed to thoroughly investigate nicotine’s effects on human platelets and its pharmacological mechanisms, using thromboelastography to assess nicotine’s impact on platelet function during coagulation. …”
    Get full text
    Article
  12. 72

    Study on the pathogenesis of pathophysiological changes of burn systemic infection by Li Ao (Ngao), Huang Yuesheng, Yang Zongcheng

    Published 1992-01-01
    “…Their changes were closely correlated with the clinical course and deterioration of systemic infection. Circulatory platelet aggregate ratio decreased significantly, while myocardiac enzyme spectrum greatly increased. …”
    Get full text
    Article
  13. 73

    The Association Between Platelet Indices and Clinical Parameters in Recurrent Pregnancy Loss by Sümeyra Nergiz Avcıoğlu, Sündüz Özlem Altınkaya, Mert Küçük, Selda Demircan Sezer, Hasan Yüksel

    Published 2014-12-01
    “…Platelet (PLT) count, mean PLT volume (MPV), PLT distribution width (PDW) and plateletcrit (PCT) are platelet indices and may be markers for increased platelet aggregability. In the present study, we aimed to determine and compare PLT count, MPV, PDW and PCT between patients with RPL and healthy controls. …”
    Get full text
    Article
  14. 74